Fig. 4.

XDmrt4-mo and XDmrt4ΔC specifically blocks Xebf2 expression. (A) In vitro-coupled transcription/translation reactions with plasmid encoding WT XDmrt4 and a mutated version of XDmrt4 (muXDmrt4) in the presence of increasing amounts of XDmrt4-mo. (B) Embryo injected in with a control morpholino shows normal expression of Xebf2 on the injected side. (C and D) Injection of 20 ng of XDmrt4-mo in one blastomere at the eight-cell stage results in a reduction or loss of Xebf2 on the injected side. (E) Another Olf/Ebf family member, Xebf3, is also reduced upon XDmrt4-mo injection. (F) However, the olfactory placode marker, XEmx2, remains unaffected under these conditions. (G–J) XBF1 (G and H) and Dlx5 (I and J) expression at stage 17 (G and I) or stage 25 (H and J) are unperturbed in XDmrt4-mo-injected embryos. (K) Schematic representation of WT and XDmrt4 deletion construct (XDmrt4ΔC). The blue box indicates the position of the DM domain. (L) Injection of 1 ng of XDmrt4ΔC mRNA results in a loss of the Xebf2 expression domain. (B–J and L) RNA encoding the lineage tracer β-gal was coinjected in all cases to identify the injected side (red staining, arrows). Anterior views are shown, dorsal to the top. (Magnifications: ×10.)